Peptide interactions with bacterial lipopolysaccharides

Current Opinion in Colloid and Interface Science

Volumn 18, Issue 5, 2013, Pages 381-392

  Schmidtchen, Artur ^a   Malmsten, Martin ^b  

^a LUND UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Anti endotoxic; Antimicrobial; Lipid A; Lipopolysaccharide; Peptide

Indexed keywords

ANTI-ENDOTOXIC; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL; ANTIMICROBIAL PEPTIDE; CHRONIC INFLAMMATION; LIPID A; LIPOPOLYSACCHARIDES; PHYSICO-CHEMICAL FACTORS;

MICROORGANISMS; PEPTIDES;

POLYSACCHARIDES;

BACTERIUM LIPOPOLYSACCHARIDE; LIPID A; PEPTIDOGLYCAN; POLYPEPTIDE ANTIBIOTIC AGENT; POLYSACCHARIDE;

ADSORPTION; ATHEROSCLEROSIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; LIPID BILAYER; MEMBRANE DAMAGE; MEMBRANE RUPTURE; NONHUMAN; PHOSPHOLIPID MEMBRANE; PHYSICAL CHEMISTRY; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN LIPID INTERACTION; PROTEIN SECONDARY STRUCTURE; REVIEW;

EID: 84882236345     PISSN: 13590294     EISSN: 18790399     Source Type: Journal    
DOI: 10.1016/j.cocis.2013.06.003     Document Type: Review

References (71)

1. French G.L. Clinical impact and relevance of antibiotic resistance. Adv Drug Deliv Rev 2005, 57:1514-1527.
2. Martin G.S., Mannino D.M., Moss M. The epidemiology of sepsis in the United States from 1979 to 2000. N Engl J Med 2003, 348:1546-1554.
3. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003, 3:710-720.
4. Brogden K.A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nat Rev Microbiol 2005, 3:238-250.
5. Elsbach P. What is the real role of antimicrobial polypeptides that can mediate several other inflammatory responses?. J Clin Invest 2003, 111:1643-1645.
6. Hancock R.E., Sahl H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006, 24:1551-1557.
7. The Antimicrobial Peptide Database http://aps.unmc.edu/AP/.
8. Strömstedt A.A., Ringstad L., Schmidtchen A., Malmsten M. Interaction between amphiphilic peptides and phospholipid membranes. Curr Opin Colloid Interface Sci 2010, 15:467-478.
9. Melo M.N., Ferre R., Castanho M.A. Antimicrobial peptides: linking partition, activity, and high membrane-bound concentrations. Nat Rev Microbiol 2009, 7:245-250.
10. Shai Y. Mode of action of membrane active antimicrobial peptides. Biopolymers 2002, 66:236-248.
11. Pokorny A., Almeida P.F.F. Kinetics of dye efflux and lipid flip-flop induced by δ-lysin in phospholipid vesicles and the mechanism of graded release by amphipathic α-helical peptides. Biochemistry 2004, 43:8846-8857.
12. Mecke A., Lee D.K., Ramamoorthy A., Orr B.G., Banaszak Holl M.M. Membrane thinning due to antimicrobial peptide binding: an atomic force microscopy study of MSI-78 in lipid bilayers. Biophys J 2005, 89:4043-4050.
13. El Jastimi R., Lafleur M. Nisin promotes the formation of non-lamellar inverted phases in unsaturated phosphatidylethanolamines. Biochim Biophys Acta 1999, 1418:97-105.
14. Snyder D.S., McIntosh T.J. The lipopolysaccharide barrier: correlation of antibiotic susceptibility with antibiotic permeability and fluorescent probe binding kinetics. Biochemistry 2000, 39:11777-11787.
15. Tack B.F., Sawai M.V., Kearney W.R., Robertson A.D., Sherman M.A., Wang W., et al. SMAP-29 has two LPS-binding sites and a central hinge. Eur J Biochem 2002, 269:1181-1189.
16. Singh S., Kasetty G., Schmidtchen A., Malmsten M. Membrane and lipopolysaccharide interactions of C-terminal peptides from S1 peptidases. Biochim Biophys Acta 2012, 1818:2244-2251.
17. Andrä J., Koch M.H., Bartels R., Brandenburg K. Biophysical characterization of endotoxin inactivation by NK-2, an antimicrobial peptide derived from mammalian NK-lysin. Antimicrob Agents Chemother 2004, 48:1593-1599.
18. Andrä J., Lohner K., Blondelle S.E., Jerala R., Moriyon I., Koch M.H., et al. Enhancement of endotoxin neutralization be coupling of a C12-alkyl chain to a lactoferricin-derived peptide. Biochem J 2005, 385:135-143.
19. Rosenfeld Y., Lev N., Shai Y. Effect of hydrophobicity to net charge ratio on antibacterial and anti-endotoxin activities of structurally similar antimicrobial peptides. Biochemistry 2010, 49:853-861.
20. Japelj B., Pristovsek P., Majerle A., Jerala R. Structural origin of endotoxin neutralization and antimicrobial activity of a lactoferrin-based peptide. J Biol Chem 2005, 280:16955-16961.
21. Rosenfeld Y., Papo N., Shai Y. Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. J Biol Chem 2006, 281:1636-1643.
22. Rosenfeld Y., Sahl H.-G., Shai Y. Parameters involved in antimicrobial and endotoxin detoxification activities of antimicrobial peptides. Biochemistry 2008, 47:6468-6478.
23. Singh S., Kalle M., Papareddy P., Schmidtchen A., Malmsten M. Lipopolysaccharide interactions of C-terminal peptides from human thrombin. Biomacromolecules 2013, 14:1482-1492.
24. Kasetty G., Papareddy P., Kalle M., Rydengård V., Mörgelin M., Albiger B., et al. Structure-activity studies and therapeutic potential of host defense peptides of human thrombin. Antimicrob Agents Chemother 2011, 55:2880-2890.
25. Ringstad L., Schmidtchen A., Malmsten M. Effect of peptide length on the interaction between consensus peptides and DOPC/DOPA bilayers. Langmuir 2006, 22:5042-5050.
26. Singh S., Kalle M., Papareddy P., Schmidtchen A., Malmsten M. Membrane and lipopolysaccharide interactions of heparin cofactor II peptides. Biochim Biophys Acta 2013, [accepted for publication]. 10.1016/j.bbamem.2013.06.015.
27. Malmsten M., Claesson P., Siegel G. Forces between sulphate layers adsorbed at hydrophobic surfaces. Langmuir 1994, 10:1274-1280.
28. Neville F., Hodges C.S., Liu C., Konovalov O., Gidalevitz D. In situ characterization of lipid A interaction with antimicrobial peptides using surface X-ray scattering. Biochim Biophys Acta 2006, 1758:232-240.
29. Yang Y., Boze H., Chemardin P., Padilla A., Moulin G., Tassanakajon A., et al. NMR structure of rALF-Pm3, an anti-lipopolysaccharide factor from shrimp: model of the possible lipid A-binding site. Biopolymers 2009, 91:207-220.
30. Brandenburg K., Jürgens G., Müller M., Fukuoka S., Koch M.H.J. Biophysical characterization of lipopolysaccharide and lipid A inactivation by lactoferrin. Biol Chem 2001, 382:1215-1225.
31. Fukuoka S., Howe J., Andrä J., Gutsmann T., Rössle M., Brandenburg K. Physico-chemical and biophysical study of the interaction of hexa- and heptaacyl lipid A from Erwinia carotovora with magainin 2-derived antimicrobial peptides. Biochim Biophys Acta 2008, 1778:2051-2057.
32. Junkes C., Harvey R.D., Bruce K.D., Dölling R., Bagheri M., Dathe M. Cyclic antimicrobial R-, W-rich peptides: the role of peptide structure and E. coli outer and inner membranes in activity and the mode of action. Eur Biophys J 2011, 40:515-528.
33. Bysell H., Malmsten M. Visualizing the interaction between poly-l-lysine and poly(acrylic acid) microgels using microscopy techniques: effects of electrostatics and peptide size. Langmuir 2006, 22:5476-5484.
34. Malmsten M., Bysell H., Hansson P. Biomacromolecules in microgels - opportunities and challenges for drug delivery. Curr Opin Colloid Interface Sci 2010, 15:435-444.
35. Schneck E., Papp-Szabo E., Quinn B.E., Konovalov O.V., Beveridge T.J., Pink D.A., et al. Calcium ions induce collapse of charged O-side chains of lipopolysaccharides from Pseudomonas aeruginosa. J R Soc Interface 2009, 6:S671-S678.
36. Kaconis Y., Kowalski I., Howe J., Brauser A., Richter W., Razquin-Olazaran I., et al. Biophysical mechanisms of endotoxin neutralization by cationic amphiphilic peptides. Biophys J 2011, 100:2652-2661.
37. Brandenburg K., Garidel P., Fukuoka S., Howe J., Koch M.H.J., Gutsmann T., et al. Molecular basis for endotoxin neutralization by amphipathic peptides derived from the α-helical cationic core-region of NK-lysin. Biophys Chem 2010, 150:80-87.
38. Roes S., Seydel U., Gutsmann T. Probing the properties of lipopolysaccharide monolayers and their interaction with the antimicrobial peptide polymyxin B by atomic force microscopy. Langmuir 2005, 21:6970-6978.
39. Schumann R.R., Leong S.R., Flaggs G.W., Gray P.W., Wright S.D., Mathison J.C., et al. Structure and function of lipopolysaccharide binding protein. Science 1990, 249:1429-1431.
40. Shimazu R., Akashi S., Ogata H., Nagai Y., Fukudome K., Miyake K., et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999, 189:1777-1782.
41. Mueller M., Lindner B., Kusumoto S., Fukase K., Schromm A.B., Seydel U. Aggregates are the biologically active units of endotoxin. J Biol Chem 2004, 279:26307-26313.
42. Bhunia A., Mohanram H., Bhattacharjya S. Lipopolysaccharide bound structures of the active fragments of fowlicidin-1, a cathelicidin family of antimicrobial and antiendotoxic peptide from chicken, determined by transferred nuclear Overhauser effect spectroscopy. Pept Sci 2009, 92:9-22.
43. Mangoni M.L., Shai Y. Temporins and their synergism against Gram-negative bacteria and in lipopolysaccharide detoxification. Biochim Biophys Acta 2009, 1788:1610-1619.
44. Mangoni M.L., Epand R.F., Rosenfeld Y., Peleg A., Barra D., Epand R.M., et al. Lipopolysaccharide, a key molecule involved in the synergism between temporins in inhibiting bacterial growth and endotoxin neutralization. J Biol Chem 2008, 283:22907-22917.
45. Srivastava S., Ghosh J.K. Introduction of a lysine residue promotes aggregation of temporin L in lipopolysaccharides and augmentation of its antiendotoxin properties. Antimicrob Agents Chemother 2013, 57:2457-2466.
46. Chen X., Howe J., Andrä J., Rössle M., Richter W., Galvao da Silva A.P., et al. Biophysical analysis of the interaction of granulysin-derived peptides with enterobacterial endotoxins. Biochim Biophys Acta 2007, 1768:2421-2431.
47. Bhunia A., Domadia P.N., Bhattacharjya Structural and thermodynamic analyses of the interaction between melittin and lipopolysaccharide. Biochim Biophys Acta 2007, 1768:3282-3291.
48. Chen C., Brock R., Luh F., Chou P.-J., Larrick J.W., Huang R.-F., et al. The solution structure of the active domain of CAP18 - a lipopolysaccharide binding protein from rabbit leukocytes. FEBS Lett 1995, 370:46-52.
49. Papo N., Shai Y. A molecular mechanism for lipopolysaccharide protection of Gram-negative bacteria from antimicrobial peptides. J Biol Chem 2005, 280:10378-10387.
50. Mishra B., Leishangthem G.D., Gill K., Singh A.K., Das S., Singh K., et al. A novel antimicrobial peptide derived from modified N-terminal domain of bovine lactoferrin: design, synthesis, activity against multidrug-resistant bacteria and Candida. Biochim Biophys Acta 2013, 1828:677-686.
51. Wei L., Yang J., He X., Mo G., Hong J., Yan X., et al. Structure and function of a potent lipopolysaccharide-binding antimicrobial and anti-inflammatory peptide. J Med Chem 2013, 56:3546-3556.
52. Kalle M., van der Plas, M.J.A., Strömdahl A.-C., Malmsten M., Mörgelin M., Schmidtchen A. The thrombin-derived peptide GKY25 modulates endotoxin-induced responses through direct interactions with macrophage/monocyte cell membranes 2013, [submitted for publication].
53. Richman M., Perelman A., Gertler A., Rahimipour S. Effective targeting of Aβ to macrophages by sonochemically prepared surface-modified protein microspheres. Biomacromolecules 2013, 14:110-116.
54. Sandgren S., Wittrup A., Cheng F., Jonsson M., Eklund E., Busch S., et al. The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis. J Biol Chem 2004, 279:17951-17956.
55. Kandler K., Shaykhiev R., Kleerman P., Klescz F., Lohoff M., Vogelmeier C., et al. The anti-microbial peptide LL-37 inhibits the activation of dendritic cells by TLR ligands. J Immunol 2006, 18:1729-1736.
56. Shaykhiev R., Sierigk J., Herr C., Krasteva G., Kummer W., Bals R. The antimicrobial peptide cathelicidin enhances activation of lung epithelial cells by LPS. FASEB J 2010, 24:4756-4766.
57. Sahay G., Alakhova D.Y., Kabanov A.V. Endocytosis of nanomedicines. J Control Release 2010, 145:182-195.
58. Tabata Y., Ikada Y. Phagocytosis of microspheres by macrophages. Adv Polym Sci 1990, 94:107-141.
59. Kasetty G., Papareddy P., Kalle M., Rydengård V., Walse B., Svensson B., et al. The C-terminal sequence of several human serine proteases encodes host defense function. J Innate Immun 2011, 3:471-482.
60. Papareddy P., Rydengård V., Pasupuleti M., Walse B., Mörgelin M., Chalupka A., et al. Proteolysis of human thrombin generates novel host defense peptides. PLoS Pathog 2011, 6:e1000857. [1-15].
61. Kalle M., Papareddy P., Kasetty G., Mörgelin M., Van der Plas M.J.A., Rydengård V., et al. Host defense peptides of thrombin modulate inflammation and coagulation in endotoxin-mediated shock and P. aeruginosa sepsis. PLoS One 2012, 7(e51313):1-11.
62. Kalle M., Papareddy P., Kasetty G., Tollefsen D.M., Malmsten M., Mörgelin M., et al. Proteolytic activation transforms heparin cofactor II into a host defense molecule. J Immunol 2013, 190:6303-6310.
63. Semple F., Dorin J.R. β-Defensins: multifunctional modulators of infection, inflammation and more?. J Innate Immun 2012, 4:337-348.
64. Pulido D., Nogues M.V., Boix E., Torrent M. Lipopolysaccharide neutralization by antimicrobial peptides: a gambit in the innate host defense strategy. J Innate Immun 2012, 4:327-336.
65. Choi K.-Y., Chow L.N.Y., Mookherjee N. Cationic host defense peptides: multifaceted role in immune modulation and inflammation. J Innate Immun 2012, 4:361-370.
66. Karima R., Matsumoto S., Higashi H., Matsushima K. The molecular pathogenesis of endotoxic shock and organ failure. Mol Med Today 1999, 3:123-132.
67. Hotchkiss R.S., Monneret G., Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013, 13:260-268.
68. Papareddy P., Kalle M., Kasetty G., Mörgelin M., Rydengård V., Albiger B., et al. C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules. J Biol Chem 2010, 285:28387-28398.
69. Papareddy P., Kalle M., Sørensen O.E., Malmsten M., Mörgelin M., Schmidtchen A. The TFPI-2 derived peptide EDC34 improves outcome in Gram-negative sepsis. PLoS Pathog 2013, [submitted for publication].
70. Pasupuleti M., Schmidtchen A., Malmsten M. Antimicrobial peptides: key components of the innate immune system. Crit Rev Biotechnol 2012, 32:143-171.
71. Bysell H., Månsson R., Hansson P., Malmsten M. Microgels and microcapsules in peptide and protein drug delivery. Adv Drug Deliv Rev 2011, 63:1172-1185.